Recreation Use of Phosphodiesterase Type 5 Inhibitors, the Other Side of Erectile Dysfunction

Giovanni Maria Fusco,Luigi Cirillo,F Mastrangelo,Francesco Romano,Ernesto Di Mauro,Gianluigi Cacace,Gianluca Spena,Anna Maria Iannicelli, Christine B. Franzese,Vincenzo Mirone,Roberto La Rocca,Luigi Napolitano

Archivio italiano di urologia andrologia（2023）

引用 0|浏览0

暂无评分

摘要

To the Editor, In 1998 Sildenafil was approved by the Food and Drug Administration as first line therapy for erectile dysfunction. Since then, phosphodiesterase type 5 inhibitors (PDE5i) represent the first-line treatment of erectile dysfunction (ED), improving physiological erectile function, sexual orgasmic function, psychological self-esteem, couples' relationship, and quality of life. [...].

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要